Natixis Has $581,000 Stake in Axonics, Inc. (NASDAQ:AXNX)

Natixis decreased its position in shares of Axonics, Inc. (NASDAQ:AXNX) by 26.7% during the 1st quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 8,418 shares of the company’s stock after selling 3,068 shares during the quarter. Natixis’ holdings in Axonics were worth $581,000 at the end of the most recent reporting period.

Several other hedge funds also recently modified their holdings of AXNX. Edgestream Partners L.P. acquired a new position in Axonics during the 1st quarter worth about $605,000. Picton Mahoney Asset Management acquired a new position in shares of Axonics in the 1st quarter valued at about $13,795,000. Entropy Technologies LP acquired a new position in shares of Axonics in the 1st quarter valued at about $622,000. ProShare Advisors LLC lifted its stake in shares of Axonics by 54.9% in the 1st quarter. ProShare Advisors LLC now owns 12,752 shares of the company’s stock valued at $880,000 after purchasing an additional 4,517 shares during the period. Finally, QRG Capital Management Inc. acquired a new position in shares of Axonics in the 1st quarter valued at about $828,000. Institutional investors and hedge funds own 99.48% of the company’s stock.

Wall Street Analyst Weigh In

Separately, Needham & Company LLC reaffirmed a “hold” rating on shares of Axonics in a research report on Monday, May 6th. Eight analysts have rated the stock with a hold rating and three have given a buy rating to the stock. According to data from MarketBeat.com, Axonics presently has an average rating of “Hold” and a consensus price target of $69.78.

Axonics Price Performance

Shares of AXNX traded up $0.28 during mid-day trading on Friday, hitting $68.47. 25,013 shares of the company’s stock traded hands, compared to its average volume of 860,242. Axonics, Inc. has a 1 year low of $48.30 and a 1 year high of $69.68. The business’s 50-day moving average price is $67.45 and its 200-day moving average price is $67.74.

Axonics (NASDAQ:AXNX) last released its quarterly earnings results on Tuesday, April 30th. The company reported ($0.38) earnings per share for the quarter, missing the consensus estimate of ($0.06) by ($0.32). Axonics had a negative net margin of 4.12% and a negative return on equity of 2.58%. The firm had revenue of $91.41 million for the quarter, compared to the consensus estimate of $89.79 million. During the same quarter in the prior year, the firm earned ($0.19) earnings per share. The company’s revenue for the quarter was up 29.4% compared to the same quarter last year. On average, equities research analysts predict that Axonics, Inc. will post 0.13 EPS for the current year.

Axonics Profile

Axonics, Inc, a medical technology company, engages in the development and commercialization of novel products for the treatment of bladder and bowel dysfunction. Its sacral neuromodulation (SNM) systems are used to treat patients with overactive bladder (OAB), including urinary urge incontinence and urinary urgency frequency, as well as fecal incontinence (FI) and non-obstructive urinary retention (UR); and rechargeable (R20) and recharge-free (F15) implantable SNM systems that delivers mild electrical pulses to the targeted sacral nerve to restore normal communication to and from the brain to reduce the symptoms of OAB, UR, and FI.